Rituxan | Rheumatoid Arthritis

Rituxan® and MabThera® (generic name: Rituximab) are antibodies used to treat rheumatoid arthritis, B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders. The widely-prescribed drug was developed by IDEC Pharmaceuticals and approved by the FDA in 1997.

In December of 2006, the manufacturer of Rituxan issued an official warning letter, advising healthcare professionals that Rituxan has been linked to deaths of lupus patients. These deaths occurred from the rare brain disease, Progressive multifocal leukoencephalopathy (PML). This drastic warning came barely a month after the manufacturer had also issued an official warning, noting that Rituxan can cause bowel obstruction and gastrointestinal perforation. In some cases reported, Rituxan patients with bowel obstruction and perforation have died from their injuries.

As of May, 2007, the official Rituxan website carries the following warnings on the home page:

Fatal Infusion Reactions: Deaths within 24 hours of RITUXAN infusion have been reported. These fatal reactions followed an infusion reaction complex, which included hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Approximately 80% of fatal infusion reactions occurred in association with the first infusion

Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of TLS following treatment of non-Hodgkin's lymphoma (NHL) patients with RITUXAN.

Severe Mucocutaneous Reactions: Severe mucocutaneous reactions, some with fatal outcome, have been reported in association with RITUXAN treatment.

Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death has been reported in patients treated with Rituxan.

The manufacturer of Rituxan warns patients to notify their doctor prior to use if they have any of the following conditions:

• Heart problems (angina, arrhythmias, etc.)
• Lung problems
• Hepatitis B virus
• High number of cancerous cells
• Kidney problems

Some of the most common side-effects noted with Rituxan use are:

• Abnormal, black, bloody, tarry stools
• Bleeding gums
• Bloating/swelling of arms, hands, face, lower legs
• Blurred vision
• Persistent cough/hoarseness
• Increased thirst/hunger/urination
• Painful urination or difficulty urinating
• Stuffy/runny nose
• Nervousness
• Nausea, vomiting
• Unusual weight gain or loss
• Vomiting

For a full list, please see the manufacturer's website at www.rituxan.com.

We have worked with many individuals and families who have been injured by dangerous drugs. If you believe Rituxan or MabThera use has put you or a loved one in danger, please fill out our Case Review Contact Form to the right on this page to find out what your case is worth.

Dangerous Drugs
News Articles

Pfizer Starts Media Ad Blitz to Address Smoking Drug Concerns
May 28 (Bloomberg) – Pfizer Inc.
(read more..)

North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)

Panel May Issue Subpoenas Related to FDA Approval on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)

Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)

F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read more..)

Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read more..)

Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read more..)

$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read more...)

FREE CASE
REVIEW FORM
*Required fields
Name:*
Address:
City:
State:
Zip Code:
Phone:
Email Address:*
Provide any additional information about your potential claim including symptoms, duration, as well as specific details on what happened to you, why you believe you have a case, your injuries, damages and any related medical care, if applicable.




Our Law Firm
5950 Berkshire Lane • Suite 410 • Dallas, TX 75225
214.526.7900 • Fax: 214.526.7910 • Toll Free: 877.308.7900
©2009 Reyes Bartolomei Browne. All Rights Reserved. Design, Programming and Optimization by Ad Cetera, Inc.